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Abstract To present the results of recurrent respiratory
papillomatosis (RRP) treatment with surgical excision and
adjuvant anti-viral cidofovir intralesional use and to exam-
ine the correlation between the cidofovir eVectiveness and
the patient previous history of multiple larynx procedures,
age, extension of lesion and dose. 32 patients with laryn-
geal papillomas were treated with cidofovir in our Depart-
ment between I.2009 and I.2011. The number of previous
RRP debulking procedures ranged from 1 to 100. The
intensity of papillomatosis diVered from one anatomic site
and moderate growth to four or Wve localizations with
heavy extension. The number of injections per patient var-
ied from 1 to 7, and the total volume of 5 mg/ml solution
varied from 2 to 33 ml. The injections were combined with
laser debulking of the lesions. In disperse papillomata, the
injections were administered in particular anatomical sites
in 4–6 weeks intervals, in massive lesions injections were
repeated in the same anatomical site in 2–4 weeks. Com-
plete remission was observed in 18 out of 32 patients. 13
patients showed remission in a place of cidofovir injection.
One patient did not react to the drug. In four patients, new
changes in injection places appeared. In two patients,
hepatic toxic side eVects were observed. Intralesional
cidofovir injection has been shown to be an eVective and
safe therapy for laryngeal papillomatosis and should be
considered in those patients who experienced disease
relapse.
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Introduction
Recurrent respiratory papillomatosis (RRP), predominantly
aVecting the larynx and trachea, is caused by human papil-
loma virus (HPV). The condition is extremely diYcult to
treat and patients usually undergo multiple surgical proce-
dures and are given toxic systemic medications to control
their disease (acyclovir, ribavirin, isotretinoin, indol-3-car-
binol, and interferon [1]). Until recently, treatment has
focused on removal of the lesions with ablation of the root
of the papilloma to prevent regrowth. Since the populariza-
tion of the CO2 laser for laryngeal surgery in the 1970s,
repeated laser ablation has been the mainstay of therapy [1],
with some patients undergoing microlaryngoscopy with
laser treatment monthly or even more frequently. However,
this method carries risks of thermal injury, web formation,
scarring, poor voice quality and, unfortunately, there is a
high rate of recurrence as lesions regrow at the sites of abla-
tion and other develop in previously seemingly uninvolved
areas. Administration of adjuvant antiviral agents is also
associated with numerous side eVects [1, 2].
Direct intralesional injection of cidofovir has found
increasing use as a primary treatment for RRP in both
children and adults [3, 4]. Cidofovir, an antiviral drug,
[(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine
or HPMPC], a nucleoside analog, is approved by the FDA
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(Food and Drug Administration) for intravenous use to treat
cytomegalovirus retinitis in patients with acquired immu-
nodeWciency syndrome. Even though it has not been
approved for topical or intralesional use, cidofovir has also
been used to treat several cutaneous and mucosal viral
lesions [5, 6]. The Wrst report of successful intralesional
injection of cidofovir directly into the respiratory papillo-
mas was described in 1995 by Van Cutsem et al. [7] in a
69-year-old patient with hypopharyngeal and esophageal
RRP. Recently, severe side eVects of intralesional cidofovir
injections have been examined and described: single case
of squamous cell carcinoma arising from squamous papil-
loma [8], association between use of cidofovir and dysplas-
tic mucosa changes [9], and induction of alterations in gene
expression associated with malignant transformation [10,
11]. Some investigators dealing with RRP have suggested
the 3–5% potential for malignant transformation of these
viral-associated lesions [12], while Lee and Rosen [13]
showed a 23% incidence of malignant transformation with
six laryngeal cancers out of 26 RRP patients. Gupta et al.
[14], on the basis of pathologic data from 13 patients, drew
the strong suggestion that spontaneous dysplasia is rela-
tively common in the setting of RRP; however, the prog-
nostic signiWcance of this Wnding persists unknown and
intralesional cidofovir therapy does not correlate with
worsening dysplastic progression.
The aim of the study was to present the results of RRP
treatment with surgical excision and adjuvant anti-viral
cidofovir intralesional use and to examine the correlation
between the cidofovir eVectiveness and the patient previous
history of multiple larynx procedures, age, extension of
lesion and dose.
Materials and methods
Between January 2009 and January 2011, 32 patients were
treated for RRP in the Department of Otolaryngology and
Laryngological Oncology in Poznaj. They were from 6- to
80-year old, mean age was 33 years. In the study group,
there were 13 females and 19 males. Localization and
extent of papillomata and the epidemiological data are
shown in Tables 1 and 2. Papillomas volume was described
according to Dikkers scale [15].
The mechanical removal or laser ablation had been a
main method of treatment for recurrent laryngeal papillomas in
the Department of Otolaryngology and Laryngological
Oncology for many years. Since 2009 new pharmacological
treatment has been additionally introduced—intralesional
cidofovir injections. In 32 patients removal of papillomas
using the Kleinsasser microlaryngoscope was performed
and all patients had intralesional injections of cidofovir.
Before the Wrst cidofovir administration majority of
patients had undergone several mechanical/laser treatment
procedures due to the recurrent nature of disease (from 2 to
more than 100) (Table 1). Cidofovir injections were given
to the areas previously cleaned mechanically or with the
laser. In anterior commissure, the drug was administered
under the stroma of papillomas due to high risk of adhesion
after mechanical treatment. Injections under control of an
operating microscope were provided within the vocal fold
into the subepithelial space of Reinke, subepithelially to the
vestibular fold, or supraglottic area. Subepithelial layer of
the hypopharynx and the entrance of the esophagus were
also injected. Single drug dose ranged from 1 to 12 ml,
average was 3 ml. Maximum volume of 12 ml was used in
only one case to inject three diVerent anatomical regions of
the larynx, hypopharynx, and entrance of the esophagus
(No. 3). The minimal 1 ml dose was applied to the limited
papilloma in one vocal fold. None of the patients was given
more than 3 mg of cidofovir per 1 kg of body weight, what
is in line with international recommendations for the use of
the drug [29]. Combined treatment of papillomas including
mechanical removal and cidofovir injections in individual
patients were repeated from 1 to 7 times. It depended on the
response to the Wrst injection and the occurrence of poten-
tial side eVects. The total dose of drug ranged from 2 to
33 ml and was extended in time to 16 months (Table 3).
The follow-up period currently ranges from 2 to 21 months
(Table 3). Each patient who had undergone cidofovir treat-
ment was examined to diagnose any organ complications.
Morphology with blood smear, urea, creatinine, ALT, AST,
and bilirubin levels was checked (before the treatment and
1 day after the injection).
Results
Papillomatous lesions were mostly located in the vocal
folds, anterior commissure, and vestibular folds. In 11
patients, the disease involved aryepiglottic folds and supra-
glottic area. In two patients, papillomatosis occurred in the
posterior commissure (No. 6 and 29). Hypopharynx and
arytenoids were occupied in Wve patients (No. 3, 4, 9, 27,
and 28). Papillomas of the entrance of the esophagus were
diagnosed in one patient (No. 3). In that patient papillomas
covered the entire hypopharynx, larynx except of the laryn-
geal surface of the epiglottis, supraglottic area, and the
entrance of the esophagus. The trachea was involved in one
patient with previous tracheostomy (No. 6). Epiglottis was
occupied in seven patients (No. 3, 5, 23, 24, 28, 30, and 32).
DiVuse disease was observed in two patients: in the Wrst
one changes occurred in three anatomical regions (No. 3)
and in the second patient in all Xoors of the larynx, trachea,
and supraglottic area up to the fourth ring of the trachea
(No. 6).Eur Arch Otorhinolaryngol (2011) 268:1305–1311 1307
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The eYciency of cidofovir treatment in the Department
of Otolaryngology and Laryngological Oncology was eval-
uated on the basis of relapse of the papillomas. After
4 weeks, each patient underwent laryngological examina-
tion and, if the papillomas were present, was qualiWed for
direct laryngoscopy and repeated cidofovir injection. A
complete remission occurred in 18 patients. Other 13
patients had complete remission in the injection site, but in
places that were not injected, persistent lesions were
observed. One patient did not react to the drug (No. 32). In
four patients, new changes in injection places appeared
(No. 3, 11, 16, and 32) (Table 3). The correlation between
extension of lesions and amount of drug was substantial but
not statistically signiWcant.
None of the patients had a local complication. All of
them were easily extubated a few minutes after microlaryn-
goscopy. Twenty-four hours after cidofovir injection no
laryngeal edema or inXammatory changes occurred. One
patient (No. 3) who had the most extensive lesions at pre-
sentation and received a dose of 20 ml of drug in 10 months
developed the whitish cloudiness of the hypopharynx epi-
thelium. Systemic side eVects were observed in three
patients (No. 1, 5, and 16). A 9-year-old boy had a weak-
ness and diarrhea for about 4 days (No. 1). However, he
Table 1 Patient data—age, 
gender, prior treatment
Patient Gender Age at the beginning of 
cidofovir therapy (years)
Number of mechanical procedures 
before cidofovir injections
Number of prior CO2 
laser procedures
1m 9 5 6
2f 2 4 0 2
3f 1 6 2 7
4m2 4 0 2
5f 3 0 0 2
6 m 21 100 3
7m3 0 5 1
8f 3 8 3 1
9 f 44 40 2
10 m 27 0 4
11 m 33 100 4
12 m 43 0 2
13 m 80 10 6
14 m 21 0 1
15 m 60 0 2
16 f 61 30 5
17 m 22 0 2
18 m 33 10 3
19 f 17 2 1
20 m 50 1 1
21 m 7 5 5
22 f 30 2 2
23 f 33 1 3
24 m 23 4 3
25 m 78 3 2
26 m 31 6 2
27 f 33 3 1
28 f 18 3 1
29 f 16 2 1
30 f 68 30 6
31 m 30 4 2
32 m 6 4 3
Mean 33 12 3
Median 30 3 2
Modus 30 0 2 m male, f female1308 Eur Arch Otorhinolaryngol (2011) 268:1305–1311
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additionally suVered from a Gilbert’s syndrome, and the
symptoms could have been associated with the defect in
detoxiWcation of the drug. Two other patients (30- and 61-
year old) had ALT and AST levels 3-fold increased 1 day
after the injection (No. 5 and 16)—the values were within
normal limits after 6 weeks of liver diet. The occurrence of
complications was not related to the drug dose. None of the
patients had skin changes, high body temperature, abnor-
mal blood morphology, changed kidney, and coagulation
parameters. Patients did not complain of breathing or swal-
lowing problems.
The relapse-free time currently ranges from 3 to
21 months (Table 3).
Discussion
Recurrent RRP is a rare, severe airway management prob-
lem occurring in both children and adults, with 2-fold more
often juvenile-onset [16–18]. Multiple investigators have
shown that use of cidofovir for RRP markedly decreases
the frequency and severity of local disease recurrence [19].
Table 2 Clinical data—localization and extent of papillomatous lesions before cidofovir treatment
Grading according to Dikkers scale: 1 sessile papilloma (unifocal or multifocal), 2 exophytic papilloma (unifocal), 3 exophytic papilloma
(multifocal) [15]
Patient Vestibule Arytenoid Aryepiglottic 
folds
Epiglottis Glottis Anterior 
commisure
Posterior 
commisure
Subglottis +
trachea
Hypopharynx Esophagus
Left Right
11 2
21 1 1 1
31 3 1 1 1 2 3
41 2 1 1
51 2
6 13
71 2 2
82
92 1 1
10 2 1
11 2 3 3 1
12 1 2 2 3 3
13 1 2
14 1 2 1
15 1 3
16 2 1 1 1 2
17 2
18 1 2 2 1
19 3 2
20 1 1
21 2 1 1
22 2 2
23 2 1 3 3 3 2
24 2 1 3 3 2 1
25 2 2 2 1
26 2
27 2 2 2
28 3 3 3 2 2 1
29 3 2 3
30 2 3 3 2 3 2
31 2 1 2
32 3 1 3 3 2Eur Arch Otorhinolaryngol (2011) 268:1305–1311 1309
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Ideal medication should eliminate papillomatous lesions in
a single setting. Although clinical experience suggests that
repeated injections are necessary, the promise still remains
that cidofovir may be more eVective, with less risk than
prior therapeutic options. The median treatment protocol
presents injections of 2.5 mg/ml every 2 weeks in 12-month
period. However, some surgeons have begun using even
higher concentrations up to 5.0 mg/ml. In 1998, Snoeck
et al. [20] reported successful treatment of 16 in 17 patients
with severe lesions by intralesional injection of cidofovir in
various volumes of 2.5 mg/ml in 2-week intervals. Case
control study published by McMurray et al. [21] showed
the eVectiveness of laser procedures with injection of
cidofovir of 5 mg/ml concentration every 2 weeks. The
highest mean cumulative dose reported in the literature is
even 348 mg [22]. Following the literature, we doubled the
concentration of cidofovir we used to use to 5.0 mg/ml and
performed injections in 2–6 weeks intervals, with mean
4-week break. The treatment schedule depended on the
extension and localization of the lesions, with maximum
total dose of 33 ml. The cumulative dose of cidofovir did
never exceed 3 mg/kg [23].
The treatment results and successful RRP eradication,
primarily thought to be excellent, nowadays have become
ambiguous. In total number of 158 patients from diVerent
trials analyzed by Chadha et al. until the year 2007 [19],
Table 3 Results of treatment
CR complete response, PR partial response, NR no response, RD residual disease (response in the place of injection, next procedures planned)
Patient Number of cidofovir 
injections
Cumulative 
dose (ml)
Period of 
injections (months)
Response to 
treatment
Current 
status
Relapse-free 
time (months)
14 9 1 6 C R F r e e 8
22 4 3 C R F r e e 2 1
3 6 33 14 CR Free 7
43 1 2 1 6 P R R D
51 5 1 C R F r e e 2 1
63 7 2 C R F r e e 1 9
71 3 1 C R F r e e 1 9
81 2 1 C R F r e e 6
93 6 1 2 P R R D
10 4 8 6 CR Free 13
11 7 24.5 16 PR RD
12 3 8 12 CR Free 7
13 1 2 1 CR Free 9
14 1 2 1 CR Free 17
15 1 2 1 CR Free 6
16 2 8.5 6 CR Free 4
17 5 15 12 CR Free 4
18 3 10 11 CR Free 4
19 2 4 3 PR RD
20 2 6 4 PR RD
21 6 16 11 PR RD
22 2 7.5 2 PR RD
23 3 15 6 CR Free 3
24 3 7 2 PR RD
25 2 5 2 CR Free 7
26 1 3 1 CR Free 6
27 1 2.5 1 PR RD
28 1 7 1 PR RD
29 1 3 1 PR RD
30 1 6 1 PR RD
31 1 2 1 PR RD
32 2 9 7 NR RD1310 Eur Arch Otorhinolaryngol (2011) 268:1305–1311
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57% of patients demonstrated complete resolution, 35%
partial response, and 8% showed no improvement. According
to Verguts et al. [24], cidofovir was a negative factor for
remission. McMurray et al. [21] were unable to prove
eYcacy of cidofovir in RRP treatment. Chadha and James
[19] concluded that there was insuYcient evidence to
support the eYciency of intralesional cidofovir in adults.
The results observed by the authors were good, but not in
all patients.
Because intralesional injection of cidofovir into the
larynx is an oV-label use of this medication, it may have
complications and risks that were previously unknown.
Although the nephrotoxic risks of systemic cidofovir
administration are well reported, only a few publications
describe the toxicity after local injection of this medication
[25]. Broekema and Dikkers [22] enlisted other side eVects
of RRP cidofovir treatment: cutaneous rash, headache,
local inXammatory response, vocal cord scarring, compro-
mised airway, disorders of hematologic, and chemical
parameters in blood. In the group examined by the authors
one case of diarrhea, one of neutropenia, two temporary
elevated levels of hepatic enzymes were observed. Surpris-
ingly, larynx oedema was never noted even if high volume
of solution (>5 ml) was injected.
Little is known of the histopathologic changes that
cidofovir may induce in the laryngeal cartilage, muscle, lig-
aments, or mucosa near the areas injected. Due to high level
of carcinogenicity of cidofovir shown in animal studies,
RRP Task Force has published guidelines for clinicians
administering this medicament [15, 26, 27]. In the literature
ongoing, discussion about dysplastic propensity of topical
cidofovir in human larynx carries on [14, 22]. Single cases
of patients who developed dysplasia during intralesional
treatment with cidofovir were reported [26,  28,  29].
Dysplasia was observed after an average period of
8 months after cidofovir treatment. Broekema and Dikkers
[22] underline that dysplasia in cidofovir group occurred in
2.7% and this percentage is concurrent with the reported
incidence of spontaneous malignant degeneration of RRP
[20]. Gupta et al. [14] conWrm that cidofovir treatment
does not induce the progression of dysplasia. In our group,
no dysplastic features in pathologic examination were
observed in pre- and post-cidofovir samples during 21 months
of follow-up, but of course the group is still under strict,
regular control.
The main goals of RPP treatment are to relieve airway
obstruction, improve voice quality, and facilitate remission.
In our opinion, the schedule of treatment should include:
mechanical/laser removal of the papillomatous lesions
combined with cidofovir injection, control visits and indi-
rect laryngoscopy (stroboscopy) in outpatient clinic every
4–6 weeks, immediate hospitalization, and another surgical
procedure in suspicion of recurrence. The way of treatment
should depend on the extension and localization of the
lesions, the response to the Wrst injection of cidofovir, and
the occurrence of potential side eVects. Maximum total
dose of cidofovir should not exceed 3 mg/kg. Due to high
toxicity of cidofovir, we recommend checking laboratory
parameters like morphology with blood smear, urea, creati-
nine, ALT, AST, and bilirubin levels before the treatment,
1 day and 4 weeks after the injection. All papillomas
should be examined histopathologically to exclude any
dysplastic features or malignant transformation.
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